Stockreport

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness...

Vanda Pharmaceuticals Inc.  (VNDA) 
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm Check Earnings Report
PDF Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. [Read more]